Correspondence should be addressed to G Occhi Email gianluca.occhi@unipd.it
Learning points:
• Pituitary neuroendocrine tumors (PitNET) in patients with tuberous sclerosis complex (TSC) are rare: only few cases have been reported in literature.
• Therapeutic approach related to mTOR signaling, such as everolimus, may be used in some patients with PitNETs as well as those with TSC.
• We reported a woman with both non-secreting PitNET and TSC; PitNET was surgically removed and classified as a silent gonadotroph tumor.
• Everolimus treatment in PitNET's-derived primary cells revealed a significant decrease in cell viability.
• Considering our case and available evidence, it is still unclear whether a PitNET is a part of TSC or just a coincidental tumor.
Background
Tuberous sclerosis complex (TSC) is an autosomal dominant multisystem hereditary cutaneous condition, characterized by multiple hamartomas that can be associated to endocrine system alterations (1, 2) . TSC is mostly caused by mutations of two tumor suppressor genes TSC1 and TSC2, encoding for hamartin and tuberin, respectively. In normal cells, hamartin and tuberin form a molecular complex involved in intracellular signaling pathways controlling cell growth and proliferation, including the mammalian target of rapamycin (mTOR) cascade. Therapeutic approach related to mTOR signaling, such as everolimus, may be used in some patients (1, 2) . In nearly 10% of cases mutations are mosaic or intronic and a comprehensive genotype-phenotype correlation is still debatable. About two thirds of TSC cases are sporadic reflecting a high spontaneous mutation rate in these genes (3) .
Some reports addressing PitNET in TSC patients suggest the possible involvement of pituitary gland alterations in the pathological process of TSC (4) . The development of pituitary tumors by nearly half of adult Eker rats -i.e. spontaneous germline TSC2 mutantsfurther supports this possible association (5) . Up to now, however, no molecular evaluation of PitNET in patients with TSC has been performed to establish the weight of this link and whether PitNET should be considered a clinical manifestation of TSC is far from being clearly understood.
Case presentation
Here we present the case of a 62-year-old Caucasian woman whose diagnosis of TSC was made after the recognition of cognitive disability and neurobehavioral abnormalities of her only 32-year-old son, developed since childhood. She presented the typical TSC brain lesions at MRI (i.e. cortical tuber and right retinal hamartoma) without other typical TSC-related manifestations (e.g. renal, pulmonary, cardiac or skin lesions) and no family history of TSC. During the last 20 years she refused medical care, but in April 2012, she complained of headache: MRI scan showed a PitNET (size: 20 × 18 × 16 mm) with suprasellar extension, bilateral cavernous sinus invasion, shortened pituitary stalk and left optic nerve compression ( 
Investigation
Neurosurgery is the first treatment choice for PitNET (6) , especially for those non-functioning, which are still orphans of medical therapy. Reduction of cell viability as a consequence of an increased apoptosis has been reported after an in vitro treatment of non-secreting PitNET with everolimus and its possible use in patients has been suggested (7) . Given the therapeutic potential of everolimus in TSC (1) and PitNETs (7) -both conditions 
After 72-h treatment, the conversion of the tetrazolium dye MTT (Sigma-Aldrich) to formazan was ascertained following manufacturer protocol. After media removal and the addition of DMSO, the solution's absorbance was measured at 550 nmbackground subtraction set at 620 nm -with a microplate reader (Victor3 V 1420 Multilabel 206 Counter, Perkin Elmer). Treatment with 1μM induced a significant 20% decrease in cell viability (P < 0.05), confirming previous reported data (7) (Fig. 2A) .
To search for the TSC disease-causative variant -and possibly associate it with pituitary adenoma development -patient's germline DNA was isolated from the peripheral blood and the genomic analysis of the entire TSC1 (NM_000368.4) and TSC2 (NM_000548.3) coding sequence and intronic boundaries was performed. The analysis retrieved no disease-associated variants with the exception of the heterozygous intronic variant c.4006-71C>T found in TSC2 (Fig. 2B) and not present either in dbSNP or in ExAC databases. The computational tools MutationTaster and Human Splicing Finder both predicted a gain of a new splice site with consequent intron retention that was, however, not confirmed by an in vitro analysis of patient's lymphocyte-derived RNA. In addition, molecular analysis on archived paraffinembedded pituitary tumoral tissues failed to identify both loss of heterozygosity in TSC2 locus (Fig. 2B ) and protein expression reduction (Fig. 2C) , as expected if this would have been a loss-of-function mutation involved in the pathogenesis of this silent gonadotroph PitNET.
Treatment
We described the treatment in the intervention paragraph.
Outcome and follow-up
Pituitary imaging (with magnetic resonance) has been performed yearly, without evidence of a recurrent pituitary adenoma. The last visit was performed in May 2018.
Discussion
As far as we know, this is the first attempt to evaluate by a molecular approach the involvement of a TSC-related gene variant in the pathogenesis of the PitNET in a TSC patient. Considering the c.4006-71C>T variant causative for TSC -that is reasonable given the frequency of intronic mutations in TSC (i.e. 5%) (3) and its absence in the normal population -we could exclude the involvement of pituitary gland alterations in the pathological process of TSC, at least in this patient. On the other hand, however, until functional data on this variant has not been gathered, we cannot exclude possible alternative genetic mechanisms causative of TSC including mosaic mutations in TSC1 regulatory regions -the mosaicism would easily explain the mild phenotype of our patient (3) -or an additional TSC causative gene. Nearly 10-15% of TSC patients lack, indeed, a conclusive molecular diagnosis (1, 2) . Although relevant, our data are thus not conclusive for establishing unequivocally the causal nature of the association between TSC and PitNET that might only be a coincidence due to the relative high prevalence of pituitary tumors in the general population (8) .
Although everolimus has been successfully tested in non-functioning and growth hormone-secreting PitNET cellular models (7, 9, 10) , very few data are available on its use in PitNET patients. Everolimus has indeed been used for treating only two patients with pituitary carcinomas resistant to repeated resections, radiations and combined treatment with chemotherapeutic agentsi.e. Temozolomide and Capecitabine -with limited effects (11, 12) . Our data corroborate the efficacy of everolimus in reducing cell viability in non-secreting PitNET and support the need of further studies for demonstrating its efficacy and safety for treating this group of tumors.
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